Weight Loss Greater With Intermittent Fasting Than Calorie Restriction
By Elana Gotkine HealthDay Reporter
MONDAY, March 31, 2025 -- An intermittent fasting (IMF) intervention yields modestly greater weight loss than daily caloric restriction (DCR) among adults with overweight or obesity, according to a study published online April 1 in the Annals of Internal Medicine.
Victoria A. Catenacci, M.D., from the University of Colorado Anschutz Medical Campus in Aurora, and colleagues compared the effects of 4:3 IMF versus DCR on changes in weight at 12 months with comprehensive behavioral support in a randomized clinical trial involving adults aged 18 to 60 years with a body mass index of 27 to 46 kg/m2. The IMF group was instructed to restrict energy intake by 80 percent on three nonconsecutive days per week, with no restriction on the other four days (4:3 IMF). The DCR group was instructed to match the weekly energy deficit by reducing daily energy intake by 34 percent. Both groups also received a high-intensity comprehensive behavioral weight loss program.
The study included 165 participants: 84 4:3 IMF and 81 DCR; 125 individuals completed the trial. The researchers found that at 12 months, 4:3 IMF showed greater reductions in weight than DCR in an intention-to-treat analysis (mean difference, 2.89 kg).
"4:3 IMF should be considered within the range of evidence-based dietary weight loss approaches," the authors write.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted March 2025
Read this next
Generative AI Model for Draft Radiological Reporting Improves Documentation Efficiency
THURSDAY, June 12, 2025 -- Clinical use of artificial intelligence (AI)-generated draft radiograph reports is associated with improved radiologist documentation efficiency while...
Real-World Weight Loss With Semaglutide, Tirzepatide Less Than That Seen in Clinical Trials
THURSDAY, June 12, 2025 -- For patients with obesity initiating pharmacotherapy with semaglutide or tirzepatide, weight loss at one year is 8.7 percent on average, which is lower...
Mitochondrial Genetics Key to Metastatic Melanoma Immunotherapy Resistance
THURSDAY, June 12, 2025 -- For patients with metastatic melanoma, mitochondrial (MT) haplogroup T (HG-T) is associated with resistance to an anti-programmed cell death...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.